Clinical trials: Depressive Disorder, Major Depressive Disorder
Depressive Disorder, Major
Study to Evaluate the Efficacy, Safety and Tolerability of Bupropion Hydrochloride Extended-release Tablet, and Escitalopram Oxalate Capsule in Subjects With Major Depressive Disorder
This multi-centre study will follow a randomised, double-blind, parallel-group, active-controlled design and will evaluate the efficacy, safety and tolerability of bupropion extended-release (XL) (300 mg/day) compared with…
- Trial name
- NCT02191397
- Testing
- Bupropion, Escitalopram
- Where
- 20 sites in China
- Volunteers
- 534 people
- Sponsor
- GlaxoSmithKline
Major Depressive Disorder, Healthy Controls
Effects of Treatment on Decision-making in Major Depression
In this trial, fifty participants with current major depressive disorder who are not receiving an antidepressant medication and fifty healthy controls will complete questionnaires and computerized tasks to assess their…
- Trial name
- NCT01916824
- Testing
- Any FDA Approved Antidepressant
- Where
- United States
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- Emory University
Depression, Depressive Disorder, Major
An Expert System to Reduce Depression in Primary Care
The purpose of this study is to determine whether a home-based intervention matched to stage of change (readiness) for using effective methods to prevent or reduce depression can improve depression outcomes in primary care.
- Trial name
- NCT00497874
- Testing
- Computer-tailored intervention
- Where
- 2 sites in United States
- Volunteers
- 902 people
- Sponsor
- Pro-Change Behavior Systems
Major Depressive Disorder
A Long-Term Study of Brexpiprazole in Patients With Major Depressive Disorder
This trial is a 52-week study to assess the safety of long-term use of brexpiprazole as adjunctive therapy in combination with an antidepressant.
- Trial name
- NCT03737474
- Testing
- Brexpiprazole
- Where
- Japan
- Volunteers
- 248 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Borderline Personality Disorder
Selective Serotonin Reuptake Inhibitors (SSRIs) in Borderline Personality Disorder
The goal of this study is to examine the effectiveness the selective serotonin reuptake inhibitor (SSRI) escitalopram (also known by the trade name "Lexapro") in reducing desire to self-harm and actual self-harming among young…
- Trial name
- NCT01103180
- Testing
- Escitalopram
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- University of Chicago
Major Depressive Disorder
A Study of LY2216684 and Digoxin in Healthy Subjects
The purpose of this study is to determine how much digoxin gets into the blood stream and how long it takes the body to get rid of it when given with LY2216684.
- Trial name
- NCT01266590
- Testing
- LY2216684, Digoxin
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Mood Disorders, Bipolar Disorder
Technology Enhanced Family Treatment
The investigators propose to enhance the scalability of family-focused therapy (FFT), a 12-session evidence-based therapy for youth at high risk for mood disorders, through augmentation with a novel mobile phone application…
- Conditions
- Mood Disorders, Bipolar Disorder, Major Depression
- Trial name
- NCT03913013
- Testing
- Family-Focused Treatment with MCC App
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- University of California, Los Angeles
Bipolar Disorder, Major Depressive Episode
Light Therapy for Bipolar Disorder. Efficacy of Light Therapy for Bipolar Depression: A Randomized Controlled Trial
The purpose of this study is to understand the efficacy of light therapy for bipolar depression.
- Trial name
- NCT00852592
- Testing
- 7000lux broad-spectrum light, 50lux dim red light
- Where
- 2 sites in United States
- Volunteers
- 46 people
- Sponsor
- Northwestern University
Postpartum Depression
A Study to Evaluate Safety and Efficacy of SAGE-547 in Participants With Moderate Postpartum Depression (547-PPD-202C)
The purpose of this study was to determine if SAGE-547 Injection infused intravenously at up to 90 μg/kg/h for 60 hours reduces depressive symptoms in participants with moderate postpartum depression (PPD) compared to placebo…
- Trial name
- NCT02942017
- Testing
- SAGE-547 90 μg/kg/h
- Where
- 32 sites in United States
- Volunteers
- 108 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Mild Cognitive Impairment, Major Depressive Disorder
Memantine Plus Es-citalopram in Elderly Depressed Patients With Cognitive Impairment
Alzheimer's disease (AD), the most common dementing disorder of later life, is a major cause of disability and death in the elderly. Although a number of theoretical causes exist, the etiology of AD is still unknown.
- Conditions
- Mild Cognitive Impairment, Major Depressive Disorder, Alzheimer's Disease
- Trial name
- NCT01876823
- Testing
- es-citalopram, Memantine
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- New York State Psychiatric Institute
Mental Disorder, Schizophrenia
A Trial to Assess a Wearable Patch's Functioning to Detect Medication Ingestion
The primary purpose of the study is to evaluate the positive detection accuracy (PDA) and detection latency measures of the D-Tect patch.
- Conditions
- Mental Disorder, Schizophrenia, Major Depressive Disorder, Bipolar I Disorder
- Trial name
- NCT06372210
- Testing
- Abilify MyCite®, D-Tect Patch
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Major Depressive Disorder, Posttraumatic Stress Disorder
Comparing Group Therapies for Veterans With Depression and PTSD
Cognitive behavioral therapy (CBT) is a brief, efficient, and effective psychotherapy for individuals with depressive and PTSD. However, CBT is largely underutilized within Veteran Affairs Medical Centers (VAMCs) due to the cost…
- Trial name
- NCT03979040
- Testing
- Group Transdiagnostic Behavior Therapy, Group Disorder-Specific Therapy (G-DSTs)
- Where
- United States
- Volunteers
- 294 people
- Sponsor
- VA Office of Research and Development
Major Depressive Disorder, Social Anxiety Disorder
Transdiagnostic Brain-Behavior Profiling to Enhance Cognitive Behavioral Therapy Response
Many patients with Major Depressive Disorder (MDD) and generalized Social Anxiety Disorder (gSAD) are treated with cognitive behavioral therapy (CBT) but few have meaningful improvement.
- Trial name
- NCT03175068
- Testing
- CBT, ST
- Where
- United States
- Volunteers
- 203 people, healthy volunteers welcome
- Sponsor
- University of Illinois Chicago
Major Depressive Disorder
Study of Repetitive Transcranial Magnetic Stimulation (rTMS) in Depressed Teens
This research study aims to test the safety and effectiveness of repetitive transcranial magnetic stimulation (rTMS) on teens with depression.
- Trial name
- NCT01502033
- Testing
- Transcranial Magnetic Stimulation
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Paul E. Croarkin
Major Depressive Disorder
A 6-Month Extension Study To The B2061032 Study To Evaluate The Safety, Tolerability, And Efficacy Of DVS SR In The Treatment Of Child And Adolescent Outpatients With MDD
This is a 6-month, open-label, flexible-dose study evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) in the Treatment of Child and Adolescent Outpatients with Major Depressive Disorder (MDD).
- Trial name
- NCT01371708
- Testing
- DVS SR
- Where
- 36 sites in United States, Chile
- Volunteers
- 283 people
- Sponsor
- Pfizer
Depression
Nurse-led Case Management for Diabetes and Cardiovascular Disease Patients With Depression
This study will evaluate the effectiveness of a nurse-led case management intervention in improving disease control and depression symptoms in adults with diabetes and/or heart disease who are also depressed.
- Trial name
- NCT00468676
- Testing
- Nurse-led case management, Treatment as usual
- Where
- United States
- Volunteers
- 214 people
- Sponsor
- University of Washington
Depressive Disorder, Major
A Study of LY2216684 in Participants With Impaired Hepatic Function
The purpose of this study is to evaluate the effect of liver function on how much of the study drug (LY2216684) gets into the blood stream and how long it takes the body to get rid of it.
- Trial name
- NCT01241435
- Testing
- LY2216684
- Where
- 3 sites in United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Depression
Treatments for Depression: Drug Versus Psychotherapy
This 4-8 month study, with a 2-year follow up period, will compare sertraline (Zoloft®), venlafaxine (Effexor®), supportive-expressive psychotherapy, and placebo to determine which is more effective in treating major depression.
- Trial name
- NCT00043550
- Testing
- Supportive Expressive Therapy, Sertraline, Venlafaxine
- Where
- United States
- Volunteers
- 156 people
- Sponsor
- University of Pennsylvania
Major Depressive Disorder, Anhedonia
Investigating the Causal Role of Prefrontal Control in Decision-making in Patients With Anhedonia
Investigating whether delta-beta cross-frequency transcranial alternating current stimulation can increase goal-directed behavior in participants with major depressive disorder and elevated symptoms of anhedonia.
- Trial name
- DEBRA (NCT05084924)
- Testing
- Cross-frequency transcranial alternating current stimulation via the NeuroConn Direct Current Stimulator Plus
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- University of North Carolina, Chapel Hill
Major Depressive Disorder
Efficacy and Safety Study of a Combination Product [Drug:BCI-024 (Buspirone) and Drug:BCI-049 (Melatonin)] to Treat Major Depressive Disorder (MDD)
The primary objective of this study are to evaluate the synergistic effect of a combination product, consisting of drug BCI-024 (buspirone) and drug BCI-049 (melatonin), in reducing symptoms of depression in patients with Major…
- Trial name
- NCT00705003
- Testing
- BCI-024: over-encapsulated Buspirone tablet 15 mg QD and BCI-049: over-encapsulated Melatonin tablet 3 mg QD, BCI-024 (Buspirone)
- Where
- 9 sites in United States
- Volunteers
- 142 people
- Sponsor
- Massachusetts General Hospital